Bruker/$BRKR
1D1W1MYTD1Y5YMAX
Capital at risk
About Bruker
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.
- Ticker
- $BRKR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 11,085
- Headquarters
- Billerica, United States
- Website
- www.bruker.com
Bruker Metrics
BasicAdvanced
$9.6B
-
-$0.70
1.28
$0.15
0.32%
Price and volume
Market cap
$9.6B
Beta
1.28
52-week high
$66.98
52-week low
$32.37
Average daily volume
2.2M
Dividend rate
$0.15
Financial strength
Current ratio
1.847
Quick ratio
0.607
Long term debt to equity
0.745
Total debt to equity
0.762
Interest coverage (TTM)
7.59%
Profitability
EBITDA (TTM)
541.1
Gross margin (TTM)
48.48%
Net profit margin (TTM)
-2.03%
Operating margin (TTM)
8.89%
Effective tax rate (TTM)
-167.63%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
3.14%
Return on equity (TTM)
-3.00%
Valuation
Price to revenue (TTM)
2.749
Price to book
4.01
Price to tangible book (TTM)
-13.5
Price to free cash flow (TTM)
296.878
Free cash flow yield (TTM)
0.34%
Free cash flow per share (TTM)
0.213
Dividend yield (TTM)
0.24%
Forward dividend yield
0.32%
Growth
Revenue change (TTM)
1.65%
Earnings per share change (TTM)
-234.94%
3-year revenue growth (CAGR)
8.84%
10-year revenue growth (CAGR)
8.00%
3-year earnings per share growth (CAGR)
-31.27%
10-year earnings per share growth (CAGR)
0.57%
10-year dividend per share growth (CAGR)
9.60%
What the Analysts think about Bruker
Analyst ratings (Buy, Hold, Sell) for Bruker stock.
Analyst projections of the future price of Bruker stock.
Bulls say / Bears say
Scientific Instruments bookings rose 10% organically in Q2 and book-to-bill stayed above 1, with especially strong orders in biopharma, semiconductor tools and energy research. That gives Bruker a healthier order pipeline and supports management’s expectation of stronger growth beyond 2026. (Bruker, StockAnalysis)
Orders in China rose more than 20% in Q2, while academic and government orders outside the US also strengthened. If those bookings convert with the usual lag, an overseas recovery could diversify Bruker away from weak US academic demand and support 2027–28 revenue. (StockAnalysis, The Motley Fool)
FY26 guidance implies only 1–2% organic revenue growth, while Q3 organic revenue is expected to be flat to slightly up after $20 million of semiconductor revenue moved into Q4. The outlook therefore depends heavily on strong year-end delivery. (Bruker, The Motley Fool)
Bruker swung to a GAAP loss of $0.41 per share in Q2 after a roughly $135 million goodwill impairment linked to its automation and spatial biology businesses. That raises concerns about acquisition execution and the quality of adjusted earnings. (Nasdaq, Longbridge)
US academic demand remained soft in Q2, and recent NIH and NSF spending had not yet translated into significant orders. If the research-funding recovery is delayed, Bruker may have to rely on cost reductions rather than broad demand growth to meet its earnings targets. (The Motley Fool, StockAnalysis)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.
Bruker Financial Performance
Revenues and expenses
Bruker Earnings Performance
Company profitability
Upcoming events
Bruker News
AllArticlesVideos
Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research
Business Wire5 days ago
Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound
MarketBeat7 days ago
Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley
Business Wire2 weeks ago
Funds containing Bruker
AllUSDGBPEUR
Fund name | Fund size | $BRKR weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.20% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.20% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.10% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.10% |
iShares MSCI World Small Cap$WSML | $9B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.